Galectin Therapeutics (FRA:PHPN) Total Stockholders Equity : €-55.24 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Galectin Therapeutics Total Stockholders Equity?

Galectin Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €-55.24 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Galectin Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was €-0.93. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Galectin Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2023 was -1.19.

Galectin Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Galectin Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics Total Stockholders Equity Chart

Galectin Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

41.04

19.89

2.32

-30.39

-55.24

Galectin Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial															-30.39	-39.83	-47.19	-47.67	-55.24

Galectin Therapeutics (FRA:PHPN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Galectin Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-55.241	-	2.038)	/	61.8529
	=	-0.93

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Galectin Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.042	+	65.786)	/	-55.241
	=	-1.19

Galectin Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Galectin Therapeutics (FRA:PHPN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (FRA:PHPN) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

GALT:USA

Address

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071

Website

https://www.galectintherapeutics.com

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Galectin Therapeutics (FRA:PHPN) Headlines

No Headlines